Cargando…
Acceptability of cancer chemoprevention trials: impact of the design
Background: Chemoprevention could significantly reduce cancer burden. Assessment of efficacy and risk/benefit balance is at best achieved through randomized clinical trials. Methods: At a periodic health examination center 1463 adults were asked to complete a questionnaire about their willingness to...
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2528072/ https://www.ncbi.nlm.nih.gov/pubmed/18769562 |
_version_ | 1782158856508407808 |
---|---|
author | Maisonneuve, Anne-Sophie Huiart, Laetitia Rabayrol, Laetitia Horsman, Doug Didelot, Remi Sobol, Hagay Eisinger, Francois |
author_facet | Maisonneuve, Anne-Sophie Huiart, Laetitia Rabayrol, Laetitia Horsman, Doug Didelot, Remi Sobol, Hagay Eisinger, Francois |
author_sort | Maisonneuve, Anne-Sophie |
collection | PubMed |
description | Background: Chemoprevention could significantly reduce cancer burden. Assessment of efficacy and risk/benefit balance is at best achieved through randomized clinical trials. Methods: At a periodic health examination center 1463 adults were asked to complete a questionnaire about their willingness to be involved in different kinds of preventive clinical trials. Results: Among the 851 respondents (58.2%), 228 (26.8%) agreed to participate in a hypothetical chemoprevention trial aimed at reducing the incidence of lung cancer and 116 (29.3%) of 396 women agreed to a breast cancer chemoprevention trial. Randomization would not restrain participation (acceptability rate: 87.7% for lung cancer and 93.0% for breast cancer). In these volunteers, short-term trials (1 year) reached a high level of acceptability: 71.5% and 73.7% for lung and breast cancer prevention respectively. In contrast long-term trials (5 years or more) were far less acceptable: 9.2% for lung cancer (OR=7.7 CI(95%) 4.4-14.0) and 10.5 % for breast cancer (OR=6.9 CI(95%) 3.2-15.8). For lung cancer prevention, the route of administration impacts on acceptability with higher rate 53.1% for a pill vs. 7.9% for a spray (OR=6.7 CI(95%) 3.6-12.9). Conclusion: Overall healthy individuals are not keen to be involved in chemo-preventive trials, the design of which could however increase the acceptability rate. |
format | Text |
id | pubmed-2528072 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-25280722008-09-03 Acceptability of cancer chemoprevention trials: impact of the design Maisonneuve, Anne-Sophie Huiart, Laetitia Rabayrol, Laetitia Horsman, Doug Didelot, Remi Sobol, Hagay Eisinger, Francois Int J Med Sci Research Paper Background: Chemoprevention could significantly reduce cancer burden. Assessment of efficacy and risk/benefit balance is at best achieved through randomized clinical trials. Methods: At a periodic health examination center 1463 adults were asked to complete a questionnaire about their willingness to be involved in different kinds of preventive clinical trials. Results: Among the 851 respondents (58.2%), 228 (26.8%) agreed to participate in a hypothetical chemoprevention trial aimed at reducing the incidence of lung cancer and 116 (29.3%) of 396 women agreed to a breast cancer chemoprevention trial. Randomization would not restrain participation (acceptability rate: 87.7% for lung cancer and 93.0% for breast cancer). In these volunteers, short-term trials (1 year) reached a high level of acceptability: 71.5% and 73.7% for lung and breast cancer prevention respectively. In contrast long-term trials (5 years or more) were far less acceptable: 9.2% for lung cancer (OR=7.7 CI(95%) 4.4-14.0) and 10.5 % for breast cancer (OR=6.9 CI(95%) 3.2-15.8). For lung cancer prevention, the route of administration impacts on acceptability with higher rate 53.1% for a pill vs. 7.9% for a spray (OR=6.7 CI(95%) 3.6-12.9). Conclusion: Overall healthy individuals are not keen to be involved in chemo-preventive trials, the design of which could however increase the acceptability rate. Ivyspring International Publisher 2008-08-22 /pmc/articles/PMC2528072/ /pubmed/18769562 Text en © Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. |
spellingShingle | Research Paper Maisonneuve, Anne-Sophie Huiart, Laetitia Rabayrol, Laetitia Horsman, Doug Didelot, Remi Sobol, Hagay Eisinger, Francois Acceptability of cancer chemoprevention trials: impact of the design |
title | Acceptability of cancer chemoprevention trials: impact of the design |
title_full | Acceptability of cancer chemoprevention trials: impact of the design |
title_fullStr | Acceptability of cancer chemoprevention trials: impact of the design |
title_full_unstemmed | Acceptability of cancer chemoprevention trials: impact of the design |
title_short | Acceptability of cancer chemoprevention trials: impact of the design |
title_sort | acceptability of cancer chemoprevention trials: impact of the design |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2528072/ https://www.ncbi.nlm.nih.gov/pubmed/18769562 |
work_keys_str_mv | AT maisonneuveannesophie acceptabilityofcancerchemopreventiontrialsimpactofthedesign AT huiartlaetitia acceptabilityofcancerchemopreventiontrialsimpactofthedesign AT rabayrollaetitia acceptabilityofcancerchemopreventiontrialsimpactofthedesign AT horsmandoug acceptabilityofcancerchemopreventiontrialsimpactofthedesign AT didelotremi acceptabilityofcancerchemopreventiontrialsimpactofthedesign AT sobolhagay acceptabilityofcancerchemopreventiontrialsimpactofthedesign AT eisingerfrancois acceptabilityofcancerchemopreventiontrialsimpactofthedesign |